You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 8, 2025

Drug Price Trends for HM STAY AWAKE


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for HM STAY AWAKE

Average Pharmacy Cost for HM STAY AWAKE

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
HM STAY AWAKE 200 MG TABLET 62011-0340-01 0.07996 EACH 2025-01-22
HM STAY AWAKE 200 MG TABLET 62011-0340-01 0.07974 EACH 2024-12-18
HM STAY AWAKE 200 MG TABLET 62011-0340-01 0.07950 EACH 2024-11-20
HM STAY AWAKE 200 MG TABLET 62011-0340-01 0.08010 EACH 2024-10-23
HM STAY AWAKE 200 MG TABLET 62011-0340-01 0.08100 EACH 2024-09-18
HM STAY AWAKE 200 MG TABLET 62011-0340-01 0.08182 EACH 2024-08-21
HM STAY AWAKE 200 MG TABLET 62011-0340-01 0.08029 EACH 2024-07-17
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for Prescription Drugs: A Focus on Affordability and Cost-Effectiveness

Introduction

The pharmaceutical market, particularly in the United States, is facing significant challenges related to affordability and cost-effectiveness. This article will delve into the current state of prescription drug pricing, the need for policy reforms, and the economic implications of high drug prices. While there isn't a specific drug named "HM STAY AWAKE," we will use examples of other high-profile medications to illustrate the broader issues and potential solutions.

The Rising Costs of Prescription Drugs

Prescription drug costs have been escalating at an alarming rate, outpacing inflation and straining both individual patients and the healthcare system. In 2023, pharmaceutical expenditures in the U.S. grew by 13.6%, reaching $722.5 billion[1].

Impact on Patients and the Healthcare System

High drug prices have severe consequences for patients. A recent poll by the Kaiser Family Foundation found that 3 in 10 American adults have not taken their medication as prescribed due to cost concerns[1]. This non-adherence can lead to poorer health outcomes and increased healthcare costs in the long run.

International Comparison

The United States faces a unique challenge in managing prescription drug costs compared to other developed nations. A 2024 RAND study revealed that prescription drug prices in the U.S. are, on average, 2.78 times higher than in 33 other OECD countries[1].

Policy Reforms to Reduce Drug Costs

Several policy reforms are being considered to make prescription drugs more affordable:

Accelerate and Expand Drug Price Negotiation

Expanding Medicare's drug price negotiation power is a key strategy. The Inflation Reduction Act (IRA) has already mandated a drug price negotiation program, which is projected to save Medicare $6 billion in 2026 alone. This program could be expanded to include more drugs, potentially generating over $450 billion in savings over a decade[1].

Reform Medicaid Drug Rebates

Reforming Medicaid drug rebates can also help reduce costs. Ensuring that rebates are tied to the actual prices paid by Medicaid programs rather than list prices can lead to significant savings.

Use of Real-World Data

Utilizing real-world data from Electronic Health Records (EHRs) can help in assessing the real-world value of drugs. This approach can inform both clinical decision-making and policy formulation, leading to more cost-effective treatment strategies[1].

Case Study: PCSK9 Inhibitors

PCSK9 inhibitors, used to treat high cholesterol, illustrate the cost-effectiveness challenges. At current prices, the incremental cost-effectiveness ratio of adding PCSK9 inhibitors to statin therapy is $337,729 per quality-adjusted life year (QALY), far exceeding the commonly accepted societal threshold of $100,000 per QALY[3].

Cost-Effectiveness Analysis

For PCSK9 inhibitors to be cost-effective, their price would need to drop by 62% to $5,459 per year. At current prices, treating one more patient with PCSK9 inhibitors would result in a net present value loss of $35,907 for private payers, highlighting the financial unsustainability of these drugs at their current prices[3].

Generic Drugs and Their Role in Cost Reduction

Generic drugs play a crucial role in reducing healthcare costs. They comprise approximately 90% of all prescriptions in the U.S. and have saved patients an estimated $2.2 trillion from 2009 to 2019. However, ensuring the quality and pharmacokinetics of generic drugs is essential to maintain their benefits and avoid drug shortages and recalls[1].

Drug Shortages and Quality Issues

Drug shortages, including those of essential medications like Cisplatin, have reached their highest levels in a decade. Poor-quality generic drugs have also led to recalls, underscoring the need for stringent quality control measures in the generic drug market[1].

Public Perception and Policy Support

Public support for drug price reforms is strong. The urgent need for policy changes is recognized by both policymakers and the public, with many advocating for more aggressive measures to control drug prices.

Industry Expert Insights

Industry experts emphasize the importance of transparency and fair pricing. For example, Dr. Khurram Nasir, in his analysis of PCSK9 inhibitors, highlights the necessity of significant price reductions to make these drugs cost-effective and financially viable for private payers[3].

Key Takeaways

  • Rising Costs: Prescription drug costs are escalating, straining patients and the healthcare system.
  • Policy Reforms: Expanding Medicare's negotiation power, reforming Medicaid rebates, and using real-world data can help reduce costs.
  • International Comparison: U.S. drug prices are significantly higher than in other OECD countries.
  • Cost-Effectiveness: Drugs like PCSK9 inhibitors need substantial price reductions to be cost-effective.
  • Generic Drugs: Generic drugs offer significant cost savings but require stringent quality control.

FAQs

What are the main drivers of high prescription drug costs in the U.S.?

The main drivers include the lack of price negotiation power, the unique structure of the prescription drug market involving Pharmaceutical Benefit Managers (PBMs), and the absence of price controls compared to other developed nations[1].

How can expanding Medicare's drug price negotiation power help reduce costs?

Expanding Medicare's negotiation power could generate over $450 billion in savings over a decade by negotiating lower prices for a larger number of drugs[1].

What is the impact of high drug prices on patient adherence?

High drug prices lead to non-adherence, with 3 in 10 American adults reporting that they have not taken their medication as prescribed due to cost concerns[1].

How do generic drugs contribute to cost reduction in healthcare?

Generic drugs save patients significant amounts by offering the same efficacy at a fraction of the cost of brand-name drugs, with estimated savings of $2.2 trillion from 2009 to 2019[1].

What is the cost-effectiveness threshold for PCSK9 inhibitors?

For PCSK9 inhibitors to be cost-effective, their price would need to drop to $5,459 per year, a 62% reduction from the current price[3].

Sources

  1. Policy Options to Reduce Prescription Drug Costs - Stanford Medicine
  2. H & M Hennes & Mauritz AB (publ) Stock Forecast - StockInvest.us
  3. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors - JAMA Cardiology
  4. Developing expertise, customising sleep, enhancing study practices - Taylor & Francis Online
  5. Holdium (HM) Price Prediction 2024, 2025–2030 - CoinCodex

More… ↓

⤷  Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.